Standard medical therapies include patient education on proper sun protection along with topical corticosteroids or oral antimalarial drugs. Topical tacrolimus and pimecrolimus have also described as effective [3, 4] . If lack of response occurs, other systemic immunosuppressive drugs may be tried [6] .
Lasers have been described as successful in treating different types of CLE, mostly DLE. Henderson et al. reported a case using CO2 laser in 1986 [7] and Zachariae firstly used argon laser to treat DLE telangiectasias [8] . The use of pulsed dye laser (PDL) to treat DLE was described in 1995 by Núñez et al. [9] ; since then, it has been used in several forms of CLE with clearance rates higher than 60% [9] [10] [11] [12] [13] [14] .
PDL improves the telangiectasic component, erythema, and scaling. Histologic examination comparing before and after PDL treatment shows reduction in the dermal lymphocytic infiltrate, more evident in the superficial papillary dermis and improvement in basal cell hydropic degeneration and pigment incontinence. A reduction of the expression of cutaneous inflammatory regulators such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) was also observed [10] . Cosmetically satisfactory results with few side effects (transient hipo/hyperpigmentation and slight scarring) are reported in most cases [9, 11-13, 15, 16] and recurrence after laser treatment is rare (3 of 14 patients with a median of 10 months follow-up) [13] .
The authors report a series of three cases, wishing to discuss the efficacy and safety of 595-nm PDL for the treatment of DLE of the eyelids.
Material and methods
Three female patients with at least one lesion of DLE located on the eyelids were treated with PDL (Table 1 ). All patients gave their informed consent prior to their inclusion in the The patients were treated with 595-nm PDL irradiation (Cynergy, Cynosure, Massachusetts, USA) using a 10 mm spot, a fluency of 8 J/cm 2 , and a single pulse of 0.5 ms. Air cooling system was set at level 4 (Cryo 6, Zimmer Medizinsysteme GmbH, Neu-Ulm, Germany) and the lesions were covered with a thin layer of ultrasound gel for epidermal protection. The eyes were protected with an intra-ocular non reflective metal shield (Cox II, Oculo-Plastik, Canada) and the laser was pointed away from the eyeballs. The lesions were treated until a purpuric end point was reached; this occasionally required double passing but pulse stacking was avoided.
Clinical improvement was assessed by comparing digital photographs of each patient taken at baseline and 4 weeks after PDL, using a specific eyelid score (Table 2) , adapted from CLE Disease Area and Severity Index (CLASI) [17] . Six different parameters were evaluated: scaling, erythema, edema, telangiectasias (these four corresponding to disease activity), dyspigmentation, and madarosis (these two corresponding to damage).
Results
The results are shown in Table 1 . The treatment was well tolerated with no need for anesthesia or analgesia. An intense purpuric response was immediately observed after PDL treatment. All the lesions responded to the treatment (Fig. 1) , with significant improvement of erythema, scaling, edema, and telangiectasias. Madarosis was irreversible in all cases. One patient had a partial response and was retreated using the same parameters with complete resolution of the lesions. No skin or ocular side effects were reported.
Discussion
All the patients had DLE lesions on the left inferior eyelid, two of them with madarosis. In all cases, PDL was used as an alternative therapy in refractory lesions. One patient had been taking hydroxychloroquine for 7 months with no response until the day of laser therapy; given the rapid resolution of the lesions after PDL therapy, we assume that the laser treatment was the preponderant factor that leads to clinical improvement. One patient had a partial response and was retreated with the same parameters at week 4, with complete resolution of the lesions at week [8] . After laser treatment, the patients were recommended strict sun avoidance, use of sunglasses, and topical sunscreens (SPF 50). There was no relapse at 6 months follow-up.
Untreated eyelid DLE often leads to scarring, ectropion, and madarosis. We highlight the good clinical response regarding the erythematosus and the telangiectasic component and the lack of effect on the madarosis. Given the rapid improvement after 1 or 2 sessions, we believe that PDL is a valid treatment for active eyelid DLE and it should be offered in an early phase of disease, in order to avoid irreversible damage. Further studies are needed to support this hypothesis.
Ocular complications such as anisocoria, uveitis, pupillary distortion, posterior synechiae, iris atrophy, nuclear cataract, visual field defect, macular hole, and retinal scarring have been reported with Diode laser (800 nm), Alexandrite laser (755 nm), and Intense Pulsed Light (IPL) (500-1200 nm), mostly related to lack of eye protection [18] [19] [20] [21] . Although PDL has a lower tissue penetration (wavelength of 595 nm), permanent visual impairment has also been reported [22] . Eye safety procedures should always be followed during periocular laser treatments. The treatment was well tolerated without no anesthesia or analgesia.
Limitations of this study include the limited number of treated patients and the short follow-up period.
Conclusions
PDL is safe and effective in treating DLE involving the eyelids. Given the significant clinical improvement in this study and the previously published good results of PDL in the treatment of CLE [7, [9] [10] [11] [12] [13] [14] 23] , we recommend early PDL treatment as an adjunctive therapy in controlling DLE disease activity.
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